Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024 report and make more profitable business decisions.
Anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis is a group of autoimmune diseases that cause inflammation and damage to small blood vessels. It is triggered by autoantibodies called ANCAs that target and attack neutrophils, a type of white blood cell. ANCA vasculitis can affect different organs or parts of the body, such as the skin, kidney, or lung. The symptoms, diagnosis, and treatment of this condition depend on the type and severity of vasculitis, as well as the organs involved. Some common types of ANCA vasculitis are granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.
The Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) drugs in development market research report provide comprehensive information on the therapeutics under development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 34 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alentis Therapeutics AGAmgen Inc
Argenx SE
AstraZeneca Plc
Bio-Thera Solutions Ltd
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chongqing Precision Biotech Co Ltd
F. Hoffmann-La Roche Ltd
Genosco Inc
GSK plc
Hansa Biopharma AB
iBio Inc
Iltoo Pharma
InflaRx NV
Jiangsu Hengrui Medicine Co Ltd
Juventas Cell Therapy Ltd
Kyowa Kirin Co Ltd
Kyverna Therapeutics Inc
Mabion SA
Mabpharm Ltd
Modulus Discovery Inc
Nippon Shinyaku Co Ltd
NovelMed Therapeutics Inc
RemeGen Co Ltd
Sana Biotechnology Inc
Santhera Pharmaceuticals Holding AG
Staidson BioPharma Inc
Teijin Pharma Ltd
Toleranzia AB
Travere Therapeutics Inc
Vertex Pharmaceuticals Inc
Visterra Inc
Table of Contents
Table
Figures
Frequently asked questions